Lynch ME, Cesar-Rittenberg P, Hohmann AG., J Pain Symptom Manage. 2013 Jun 4. pii: S0885-3924(13)00238-8. doi: 10.1016/j.jpainsymman.2013.02.018. [Epub ahead of print]
Datum van publicatie:
dinsdag, 04 juni 2013

Context: Neuropathic pain caused by chemotherapy limits dosing and duration of potentially life-saving anti-cancer treatment and impairs quality of life.

Zhong W, Yu Z, Zeng JX, Lin Y, Yu T, Min XH, Yuan YH, Chen QK., Pain Pract. 2013 May 20. doi: 10.1111/papr.12083. [Epub ahead of print]
Datum van publicatie:
maandag, 20 mei 2013

Pancreatic ductal adenocarcinoma has a high rate of neural invasion (80 to 100%) and can be associated with moderate to severe pain in pancreatic cancer.

Mejdahl MK, Andersen KG, Gärtner R, Kroman N, Kehlet H., BMJ. 2013 Apr 11;346:f1865. doi: 10.1136/bmj.f1865.
Datum van publicatie:
donderdag, 11 april 2013

Objective: To examine the development of persistent pain after treatment for breast cancer and to examine risk factors associated with continuing pain.

Davies A, Buchanan A, Zeppetella et al., J Pain Symptom Manage. 2013 Mar 22. pii: S0885-3924(13)00120-6. doi: 10.1016/j.jpainsymman.2012.12.009.
Datum van publicatie:
vrijdag, 22 maart 2013

Context: Breakthrough pain is common in patients with cancer and is a significant cause of morbidity in this group of patients.

Loh J, Gulati A., Pain Med. 2013 Feb 25. doi: 10.1111/pme.12038. [Epub ahead of print]
Datum van publicatie:
maandag, 25 februari 2013

Background: Cancer pain is difficult to treat, often requiring a multimodal approach.

Pagina's ©2012    -    -    colofon    -    disclaimer    -    privacy    -    online by:

Stichting Pain Research Delft    TEVA    Therabel